The Pharmaceutical Market: Ireland

Publisher Name :
Date:25-Apr-2013
No. of pages:

THE PHARMACEUTICAL MARKET: IRELAND – REVIEW

Ireland has experienced rapid economic growth over the past 20 years, and has invested in large scale renovation and redevelopment of its healthcare infrastructure. That said, the country is in the midst of a severe economic downturn, with GDP expected to contract in 2012. Due to the recession and Ireland’s huge budget deficit, the country has received an 85 billion euro (US$113 billion) bailout from the EU and IMF. As a result, the government faces an extremely tight financial operating environment in the next few years. It has generally sought to protect healthcare, especially frontline services, from the kinds of cuts experienced elsewhere, but health is not unaffected. A progression of measures has been introduced as the economic position has worsened, most recently the Budget 2011 and related National Recovery Plan.

In March 2011, the government announced plans to introduce Universal Health Insurance (UHI) by 2016. Underpinning the UHI system will be the principle of access according to need and payment according to ability to pay. Insurance with a public or private insurer will be compulsory, with insurance payments related to ability to pay. The government is also planning to remove fees for GP care, which will be implemented in phases, firstly for claimants of free drugs under the Long-Term Illness scheme and the High-Tech Drugs scheme, before being extended to all. Under UHI, public hospitals will no longer be managed by the HSE. They will be independent, not-for-profit trusts with managers accountable to their boards. Hospitals will be paid according to the care they deliver and will be incentivised to deliver more care in a ‘money follows the patient’ system. The government has also reiterated plans to introduce reference pricing and generic substitution, as cost saving measures.

Most global companies have some manufacturing presence in the pharmaceutical market in Ireland. Drugs are either produced in finished form for export, or exported on to other facilities for finishing. A number of branded drugs go off patent in 2012, including Pfizer’s Lipitor and Eli Lilly’s Zyprexa, which could have a negative impact on the industry. However, several multinational companies have been moving into the biologic sector in preparation for the loss of profit from these blockbuster drugs. While the multinational presence is very strong, Ireland has very few domestic producers. In September 2011, Alkermes completed its merger with Elan Drug Technologies (EDT) to form a new company, Alkermes Plc., which is headquartered in Dublin. In September 2011, Pfizer announced it was to invest US$200.0 million at its Grange Castle site, to add two processing suites and to expand current production and product testing capabilities. In September 2011, MSD opened its new R&D centre at its Ballydine site, creating 70 new jobs. Previously, in June 2011, MSD opened two new facilities at the site in Brinny.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

The Pharmaceutical Market: Ireland

Table Of Contents
N/A

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Poland Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 116
    BMI View: Polish pharmacies reported flat year-on-year growth in Q114 sales data. However, BMI expect growth to pick up in the remaining quarters of the year as the country's exports increase and household consumption rises. We highlight consumer healthcare products, especially over-the-counter medicines, as a particularly attractive growth area. Poland's lack of exposure to Russia and the regional tension reinforces our view that the country is one of the most attractive markets in Central and ......
  • Kenya Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 105
    BMI View: The growing Kenyan population will support the growth of the country's pharmaceuticals and healthcare industry. While fertility rates have dropped over the last decade, from 5.0 births per woman in 2003 to 4.4 births per woman in 2013, we note that these figures are well above developed state fertility rates. In 2009, the EU-27 average stood at 1.59 live births per woman. However, we note that the country's young population will act as a limiting factor for pharmaceutical demand, prese......
  • Germany Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 134
    BMI View: Germany's medicines pricing regime will continue to restrict drugmakers' revenue streams. The AMNOG has proved to be tough, with the majority of medicine reimbursement prices lying under the average of or below the lowest of the European reference country basket. Additionally, legislators have voted to continue the 2010 implemented price freeze on reimbursed drugs until the end of 2017. However, the long term and clear nature of the measures implemented by the government is a much more......
  • Canada Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 122
    BMI View: The Canadian pharmaceutical and healthcare market will become increasingly attractive to pharmaceutical companies over the next few years as economic growth in the country gradually accelerates. The hospitable business environment, improving healthcare coverage and broader drug reimbursement lists will continue to provide revenue-generating opportunities for drugmakers. Headline Expenditure Projections ? Pharmaceuticals: CAD25.6bn (USD24.9bn) in 2013 to CAD25.9bn (USD22.5bn) in 2014; +......
  • Turkey Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 125
    BMI View: Data released by the Turkish drugmakers association for 2013 sales corresponds with our own forecasts. We have also modified our pharmaceutical sales forecast for 2014 and beyond to reflect the volatile exchange rate situation. We now see Turkey's lustre as an emerging pharmaceutical market regressing over the medium term. We believe that the business environment will continue to impede the industry and see very little scope for the central government to enact business-friendly reform ......
  • Cameroon Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 58
    BMI View: Mobile health has strong growth potential in Cameroon, given the lack of health infrastructure and medical professionals. The use of mobile health will help to improve accessibility to healthcare, to some extent. However, we maintain that in order for Cameroon to reach its full potential, there needs to be much greater commitment to invest in healthcare services. Headline Expenditure Projections ? Pharmaceuticals: XAF148.82bn (USD300mn) in 2013 to XAF166.95bn (USD320mn) in 2014; +12.2%......
  • Tanzania Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 69
    BMI View: Sourcing accurate and reliable quantitative data on Tanzania's pharmaceutical market remains challenging due to substandard audits, porous sales channels, a high prevalence of counterfeits, questionable national statistics, dispensing without prescriptions, sizeable 'grey markets' and the widespread use of traditional remedies. BMI takes into account the import dependence of countries for medicines and assumes that economic growth as well as the resulting increase in the size of Tanzan......
  • Bulgaria Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 101
    BMI View: The Ministry of Health's plan to increase MAH fees, coupled with price cuts for generic drugs and freezes on OTC medicine prices indicate that the Bulgarian pharmaceutical market will not see meaningful growth in 2014. However, we expect a pickup in demand for innovative drugs to reinvigorate interest in the country, although it will continue to present a relatively small opportunity for drugmakers in the region. Headline Expenditure Projections ? Pharmaceuticals: BGN2.32bn (USD1.58bn)......
  • Taiwan Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 136
    BMI View: BMI believes that cost-containment policies will not place significant pressure on healthcare expenditure in Taiwan. This is because the majority of spending in the medical services sector goes towards salaries for doctors and nurses, which are difficult to cut back on without arousing political opposition. Meanwhile, the needs of the ageing population mean that demand is increasing for innovative pharmaceuticals and medical devices, which will sustain higher health expenditure. Taiwan......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs